National Courier Ass'n v. Board of Governors, 516 F.2d 1229, 1237 (D.C. Cir. 1975). In addition, the Board may consider any other basis that may demonstrate that the activity has a reasonable or close relationship to banking or managing or controlling banks. Board Statement Regarding Regulation Y, 49 FR 806 (1984).

The Board has previously approved, by regulation, providing investment and financial advisory services, 12 CFR 225.25(b)(4)(i)-(v) and (vi)(A)(1) and (2), providing investment advice to nonaffiliated persons with respect to the purchase and sale of financial futures contracts and options on such futures contracts, 12 CFR 225.25(b)(19) and trust services, 12 CFR 225.25(b)(3). Applicant has stated that it would conduct these proposed activities subject to the requirements and limitations of the Board's Regulation Y.

The Board also has previously determined by order that the provision of investment advisory services with respect to financial futures and options on futures contracts on bonds, interest rates and stock and bond indexes is a permissible activity pursuant to Section 4(c)(8) of the BHC Act. See SR 93-27; National Westminster Bank PLC, 78 Federal Reserve Bulletin 953 (1992); Manufacturers Hanover Corporation, 76 Federal Reserve Bulletin 774 (1990); and The HongKong and Shanghai Banking Corporation, 76 Federal Reserve Bulletin 770 (1990). The Board has also approved the providing of investment advice through limited partnerships. See Meridian Bancorporation, 80 Federal Reserve Bulletin 736 (1994). Applicant proposes to comply with commitments similar to those relied on by the Board in Meridian, but seeks, in the alternative, a determination that Brinson Partners does not control the limited partnerships for purposes of the Bank Holding Company Act, or, if it is deemed to control the partnerships, 'grandfather" treatment for four existing limited partnerships that Brinson Partners serves as general partner.

In order to satisfy the proper incident to banking test, section 4(c)(8) of the BHC Act requires the Board to find that the performance of the activities by Company can reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interest, or unsound banking practices. Applicant believes that the proposed activities will benefit the public by providing access by customers of Applicant to the institutional asset management experience and expertise of Brinson Partners and by permitting Applicant to draw on such experience and expertise to enhance its investment advisory products and services. Applicant believes that competition will be fostered by enhancing the ability of Applicant to compete in the asset management arena with sophisticated competitors as a result of the combination of Applicant's existing institutional asset management business with that of Brinson Partners and Brinson Trust. Applicant further believes that the proposal will not result in adverse effects.

In publishing the proposal for comment, the Board does not take a position on issues raised by the proposal. Notice of the proposal is published solely in order to seek the views of interested persons on the issues presented by the application and does not represent a determination by the Board that the proposal meets, or is likely to meet, the standards of the BHC Act.

Any comments or requests for hearing should be submitted in writing and received by William W. Wiles, Secretary, Board of Governors of the Federal Reserve System, Washington, D.C. 20551, not later than March 8, 1995. Any request for a hearing on this application must, as required by § 262.3(e) of the Board's Rules of Procedure (12 CFR 262.3(e)), be

accompanied by a statement of the reasons why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

This application may be inspected at the offices of the Board of Governors or the Federal Reserve Bank of New York.

Board of Governors of the Federal Reserve System, February 16, 1995.

# William W. Wiles,

Secretary of the Board.
[FR Doc. 95-4348 Filed 2-22-95; 8:45 am]
BILLING CODE 6210-01-F

# FEDERAL TRADE COMMISSION

# Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

# TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 013095 AND 021095

Name of acquiring person, name of acquired person, name of acquired entity	PMN No.	Date termi- nated
The Foothill Group, Inc., Norfolk Shipbuilding & Drydock Corporation, Flagship Financial Corporation	95–0835	01/30/95
Cilluffo Associates, L.P., Stone & Webster, Incorporated, Stone & Webster, Incorporated,	95-0795	01/31/95
Cilluffo Associates, L.P., GRC International, Inc., GRC International, Inc.	95-0796	01/31/95
AT&T Corp., GFC Financial Corporation Greyhound Financial Corporation	95-0881	01/31/95
BASF Aktiengesellschaft, The Boots Company, The Boots Company (USA) Inc.	95-0830	02/01/95
Value Health, Inc., Group Hospitalization and Medical Services, Inc., Health Management Strategies Inter-		
national, Inc.	95-0832	02/01/95
Sears, Roebuck and Co., Federated Department Stories, Inc., Stern's Department Stores, Inc.	95-0834	02/01/95
E. I. DuPont de Nemours and Company, Amoco Corporation, Amoco Production Company	95-0859	02/01/95
Amoco Corporation, E. I. DuPont de Nemours and Company, Conoco, Inc.	95-0860	02/01/95
Kidd, Kamm Equity Partners, L.P., Irving and Audrey Gronsky, Bristol Foods, Inc.	95-0896	02/01/95

#### TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 013095 AND 021095—Continued

Name of acquiring person, name of acquired person, name of acquired entity	PMN No.	Date termi- nated
Harbour Group Investments III, L.P., DelCorp Incorporated, DelCorp Incorporated	95–0901	02/01/95
Penn Virginia Corporation, United Meridian Corporation, UMC Petroleum Corporation	95-0903	02/01/95
Philipp Holzmann, A.G., Costain Group PLC, The Dolet Hills Mining Venture	95–0905	02/01/95
North Shore Regional, Health System, Huntington Hospital, Huntington Hospital	95–0822	02/03/95
Archer-Daniels-Midland Company, Archer-Daniels-Midland Company, Independent Soy Processors Company	95–0895	02/03/95
USF&G Corporation, Victoria Financial Corporation, Victoria Financial Corporation	95–0897	02/03/95
La-Z Boy Chair Company, England/Corsair, Inc., England/Corsair, Inc.	95–0912	02/03/95
Siemens Aktiengesellschaft, Pyramid Technology Corporation, Pyramid Technology Corporation	95–0913	02/03/95
Corporate Express, Inc., G. Lynn Shostack, Joyce International, Inc.	95–0926	02/03/95
HBE Corporation, Barclays PLC, Pawnee-Daytona Inc.	95–0965	02/03/95
Logicon, Inc., Harnischfeger Industries, Inc., Syscon Corporation	95–0920	02/06/95
Corning Incorporated, Corning BioPro Inc., Corning BioPro Inc	95–0928	02/06/95
United Healthcare Corporation, Luis A. Salgado Torres, Group Sales and Service of Puerto Rico, Inc	95–0958	02/06/95
Molex Incorporated, Mod-Tap W Corp., Mod-Tap W Corp.	95–0886	02/07/95
Alma Energy Corp., Unocal Corporation, Union Oil Company of California	95–0932	02/07/95
The Horne Family Voting Trust, Anderson Family Trust, Anderson-Barrows Metals Corporation	95–0943	02/07/95
Pharmacia AB, Ms. Jacqueline Hoefer, Hoefer Scientific Instruments	95–0756	02/09/95
Mallinckrodt Group Inc., The Procter & Gamble Company, J. T. Baker Inc.	95–0737	02/10/95
Coats Viyella Plc, BACE Manufacturing, Inc., BACE Manufacturing, Inc.	95–0918	02/10/95
Ronald O. Perelman, Abex Inc., Abex Inc.	95–0929	02/10/95
The News Corporation Limited, SCS Communications, Inc., Westview Press, Inc.	95–0944	02/10/95
Ashland Oil, Inc., Mr. Ira L. Morris and Mrs. Betty Sue Morris, Waco Oil & Gas Co., Inc.	95–0949	02/10/95
Vincent J. Ryan, James F. Knott, National Business Archives, Inc.	95–0955	02/10/95
VIAG AG, AmeriQuest Technologies, Inc., AmeriQuest Technologies, Inc	95–0956	02/10/95
Beverly Enterprises, Inc., Pharmacy Management Services, Inc., Pharmacy Management Services, Inc	95–0960	02/10/95
Pennzoil Company, Limited Liability Company, Limited Liability Company	95–0961	02/10/95
The Brooklyn Union Gas Company, Limited Liability Company, Limited Liability Company	95–0962	02/10/95
Possession)	95-0963	02/10/95
Precision Castparts Corp., Columbus II Limited Partnership, Quamco, Inc.	95–0970	02/10/95
William Herbert Hunt Trust Estate, Texaco Inc., Texaco Exploration and Production Inc.	95–0978	02/10/95
National Gaming Corp., Part-A-Dice Gaming Corporation, Par-A-Dice Gaming Corporation	95–0980	02/10/95
Sonat Inc., Hardy Oil & Gas PLC (a Britishcompany), Hardy Holdings, Inc.	95–0993	02/10/95

#### FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Renee A. Horton, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, D.C. 20580, (202) 326–3100.

By direction of the Commission.

#### Donald S. Clark,

Secretary.

[FR Doc. 95–4396 Filed 2–22–95; 8:45 am]

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

Availability of Draft U.S. Public Health Service Recommendations for HIV Counseling and Testing for Pregnant Women

**AGENCY:** Centers for Disease Control and Prevention (CDC), Public Health Service (PHS), Department of Health and Human Services.

**ACTION:** Notice of availability and request for comments.

SUMMARY: This notice announces the availability for review and comment of a draft document entitled "U.S. Public Health Service Recommendations for HIV Counseling and Testing for Pregnant Women." The document was prepared by CDC staff in collaboration with other internal PHS and external consultants.

DATES: To ensure consideration, written comments on this draft document must be received on or before April 10, 1995. **ADDRESSES:** Requests for copies of the draft recommendations must be submitted to the CDC National AIDS Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003, telephone (800) 458-5231. Written comments on the draft document should be sent by mail or facsimile to the Technical Information Activity, Division of HIV/ AIDS, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Mailstop E-49, 1600 Clifton Road, NE., Atlanta, GA 30333, facsimile (404) 639-2007, for receipt by April 10, 1995.

FOR FURTHER INFORMATION CONTACT: Technical Information Activity, Division of HIV/AIDS, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Mailstop E-49, Atlanta, GA 30333.

SUPPLEMENTARY INFORMATION: In February 1994, the National Institutes of Health announced interim results from AIDS Clinical Trial Group (ACTG) protocol 076 indicating that zidovudine (ZDV) therapy administered to a select group of HIV-infected pregnant women and their newborns reduced the risk of perinatal HIV transmission by approximately two thirds. In April 1994, provisional recommendations for the use of ZDV therapy in HIV-infected pregnant women and their newborns were published. In June 1994, representatives from Federal and nonfederal health agencies and other organizations attended a meeting in Bethesda, Maryland, to discuss development of U.S. Public Health Service recommendations to prevent perinatal HIV transmission and the implications of those recommendations for HIV treatment, counseling, and HIV testing. In August 1994, the U.S. Public Health Service published recommendations for ZDV therapy to reduce the risk of perinatal transmission of HIV (also available from the CDC